A critical appraisal of the potential benefit of post-operative structured follow-up after resection for biliary tract cancer

Lynn E. Nooijen(Vrije Universiteit Amsterdam), Joris I. Erdmann(Amsterdam University Medical Centers), Geert Kazemier(European Organisation for Research and Treatment of Cancer), Lizzel van der Snee(Dutch Cancer Society), John Bridgewater(University College London Hospitals NHS Foundation Trust), John Primrose(University of Southampton), B. Ten Haaft(University of Amsterdam), Heinz‐Josef Klümpen(University Medical Center Groningen)
HPB
October 11, 2023
10.1016/j.hpb.2023.10.004
Cited by 1

Related Papers

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
A DNA methylation fingerprint of 1628 human samples
|Genome Research|2011|418